ArticleBMC pediatrics2025
Emphysema: an ignored radiologic sign of diffuse alveolar hemorrhage.
Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundDiffuse alveolar hemorrhage (DAH) is characterized by the presence of diffuse ground glass opacities and/or consolidation on chest CT. Emphysema has been reported occasionally. Nevertheless, the pathogenesis, incidence, imaging subtypes, and clinical impact of emphysema in patients with DAH are still unclear.
methodsThis was a retrospective clinical study. Children with DAH who were admitted to our hospital between January 2013 and December 2019 were included. All chest CT images of the patients were analyzed by two board-certified thoracic radiologists. The clinical features of the patients with diffuse emphysema were further analyzed. A matched case-control study was performed to explore the risk factors for developing diffuse emphysema.
resultsNinety-four patients were included. Chest CT scans revealed emphysema in 28 patients (29.8%). Paraseptal emphysema (n = 24) was the most common imaging subtype. The median interval between the onset and development of emphysema was 11.0 months (n = 18, range: 2-113 months). Nine cases developed diffuse emphysema, in which six cases had persistent dyspnea and exercise intolerance, nine cases had persistent ground-glass opacities and 8 cases had a delay in initial treatment of 12 or more months. Compared to those in the matched control group, the interval between the onset and start of regular therapy with glucocorticoids was significantly longer in the cases with diffuse emphysema (median interval 13.5 vs. 1.5 months, P < 0.01).
conclusionsIn cases with DAH, emphysema is a relatively common but ignored radiologic sign and diffuse emphysema seems to be a sign of irreversible lung function impairment. A delay in initial treatment is a risk factor for developing diffuse emphysema.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.